Kyoto iCAP fund invests additional JPY 300 million in Orizuru Therapeutics

PUBT · 2d ago
Kyoto iCAP fund invests additional JPY 300 million in Orizuru Therapeutics
  • Kyoto University Innovation Capital’s KYOTO-iCAP2 fund made an additional equity investment of about JPY 300 million in Orizuru Therapeutics.
  • Orizuru develops iPS cell-derived therapies, including a pancreatic islet cell sheet for type 1 diabetes.
  • Orizuru’s OZTx-410 is in a physician-led safety trial at Kyoto University Hospital, with patient transplants starting in April 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyoto University Innovation Capital Co Ltd published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.